On Monday, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE:GSK).

The update follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to advance the WVE-006 program in alpha-1 antitrypsin deficiency (AATD), a rare condition.

AATD is an inherited genetic disorder caused by SERPINA1 gene mutations, resulting in low levels of a protective protein (AAT) that leads to severe, early-onset emphysema/COPD and liver disease.

The agreement was made prior to data becoming available from the next cohort of the RestorAATion-2 trial, which remains ...